EN | UA
EN | UA

Help Support

Back

Clinical efficacy of subcutaneous tocilizumab to treat rheumatoid arthritis

Clinical efficacy of subcutaneous tocilizumab to treat rheumatoid arthritis Clinical efficacy of subcutaneous tocilizumab to treat rheumatoid arthritis
Clinical efficacy of subcutaneous tocilizumab to treat rheumatoid arthritis Clinical efficacy of subcutaneous tocilizumab to treat rheumatoid arthritis

An open-label, single-arm, multicentre, 24-week study was carried to investigate the efficacy of subcutaneous tocilizumab therapy in rheumatoid arthritis patients and to determine the response by ultrasound in comparison with CDAS.

See All

Key take away

In rheumatoid arthritis patients treated with subcutaneous tocilizumab, the clinical and ultrasound scores rapidly declined. Ultrasound scores were not linked with participant-reported variables. Half of the subjects attained ultrasound remission, while there was a rise in discrepancies in the proportion of subjects attaining remission based on different Composite Disease Activity Scores (CDAS).

Background

An open-label, single-arm, multicentre, 24-week study was carried to investigate the efficacy of subcutaneous tocilizumab therapy in rheumatoid arthritis patients and to determine the response by ultrasound in comparison with CDAS.

Method

The study cohort included rheumatoid arthritis subjects with an unsatisfactory response to conventional synthetic disease-modifying anti-rheumatic agents initiating subcutaneous tocilizumab 162 mg once weekly for about 24 weeks. The clinical evaluations were carried at baseline, two, four, eight, 12, 16, 20, and 24 weeks and the ultrasound assessments were carried out at baseline, 4, 12, and 24 weeks.

Estimation of sum scores of ultrasound greyscale/Doppler, and CDAS and American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) response were done. Utilizing the Mann-Whitney test and correlations by Spearman's rho, the alterations during follow-up were determined.

Result

Overall, 133 subjects were clinically evaluated and 110 subjects were also assessed with ultrasound. All ultrasound and clinical scores remarkably declined after four weeks. At 24 weeks, ACR 70% response in 47.4% and EULAR good response was witnessed in 87.7%. The ultrasound scores were found to have no or low correlations with participant-reported outcomes. At 24 weeks, a sum score Doppler of 0 was noted in 53.3% and CDAS remission was attained in 27.4-83.5%.

Conclusion

Subcutaneous tocilizumab therapy yields satisfactory outcomes in rheumatoid arthritis patients.

Source:

Scandinavian Journal of Rheumatology

Article:

Major reduction of ultrasound-detected synovitis during subcutaneous tocilizumab treatment: results from a multicentre 24 week study of patients with rheumatoid arthritis

Authors:

H B Hammer et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: